The use of intravitreal VEGF Trap-Eye for the treatment of neovascular AMD has recently been evaluated in two phase III clinical trials: the North American VIEW 1 study and the international VIEW 2 study (VIEW: “VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD”). Here, VEGFA is linked to age-related macular degeneration.